维奈克拉在高危复发性套细胞淋巴瘤中的疗效:维奈克拉耐药患者的结局与突变谱
该研究描述了24例接受维奈克拉方案治疗的多重复发套细胞淋巴瘤患者的临床结局与基因组特征,中位既往治疗线数为5线,67%在BTK抑制剂治疗后进展,54%为母细胞样或多形性组织学。维奈克拉治疗后中位随访17个月,总缓解率50%、完全缓解率21%,中位无进展生存、总生存及维奈克拉后生存分别为8、13.5和7.3个月。对7例患者(含5对治疗前后样本)行全外显子组测序,发现SMARCA4和BCL2改变仅在进展后出现,TP53、CDKN2A、KMT2D、CELSR3、CCND1、NOTCH2和ATM在进展后改变频率增加2-4倍,提示维奈克拉耐药主要与非BCL2基因突变相关。
要点
- 24例多重复发套细胞淋巴瘤患者接受维奈克拉方案,总缓解率50%、完全缓解率21%。
- 中位无进展生存8个月,中位总生存13.5个月,维奈克拉后中位生存7.3个月。
- 进展后SMARCA4和BCL2改变新出现,TP53等基因改变频率增加2-4倍。
核心结论
- 维奈克拉耐药套细胞淋巴瘤的突变动态显示,耐药主要与非BCL2基因突变相关。
研究设计与样本
- 描述24例接受维奈克拉方案治疗的多重复发套细胞淋巴瘤患者(中位既往治疗5线)的临床结局与基因组特征。
- 对7例患者(包括5对维奈克拉治疗前与进展后样本)行全外显子组测序。
主要发现
- 67%的患者在BTK抑制剂治疗后进展,54%为母细胞样或多形性组织学。
- 维奈克拉治疗后中位随访17个月,总缓解率50%,完全缓解率21%,16例进展、15例死亡。
- 中位无进展生存8个月,中位总生存13.5个月,维奈克拉后中位生存7.3个月。
- SMARCA4和BCL2改变仅在进展后出现,TP53、CDKN2A、KMT2D、CELSR3、CCND1、NOTCH2和ATM在进展后改变频率增加2-4倍。
- 2例系列样本患者中,进展时出现新的SMARCA4和KMT2C/D突变克隆演化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venetoclax is effective in relapsed patients with mantle cell lymphoma (MCL). Mechanisms of resistance to venetoclax in MCL are poorly understood. We describe the clinical outcomes and genomic characteristics of 24 multiply relapsed patients (median of five prior lines of therapy) who received venetoclax-based therapies; 67% had progressed on BTK inhibitors (BTKi) and 54% had blastoid or pleomorphic histology. Median follow up after venetoclax treatment was 17 months. The overall response rate was 50% and complete response (CR) rate was 21%, 16 patients had progressed and 15 died. The median progression free, overall and post venetoclax survival were 8, 13.5 and 7.3 months respectively. Whole-exome sequencing (WES) was performed on samples collected from seven patients (including five pairs; before starting venetoclax and after progression on venetoclax). The SMARCA4 and BCL2 alterations were noted only after progression, while TP53, CDKN2A, KMT2D, CELSR3, CCND1, NOTCH2 and ATM were altered 2-4-fold more frequently after progression. In two patients with serial samples, we demonstrated clonal evolution of novel SMARCA4 and KMT2C/D mutations at progression. Mutation dynamics in venetoclax resistant MCL is demonstrated. Our data indicates that venetoclax resistance in MCL is predominantly associated with non-BCL2 gene mutations. Further studies are ongoing in MCL patients to evaluate the efficacy of venetoclax in combination with other agents and understand the biology of venetoclax resistance in MCL.
引用
- Zhao S, Kanagal-Shamanna R, Navsaria L, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020. PMID: 32239765. doi:10.1002/ajh.25796
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。